Singapore: AI Biochip Speeds Up Genetic Marker Detection to 20 Minutes

Why It Matters

The technology dramatically shortens molecular diagnostic turnaround, enabling faster clinical decisions and supporting personalized medicine at scale. Its portability and AI automation could transform disease screening and accelerate drug development pipelines.

Key Takeaways

• AI biochip detects microRNAs in 20 minutes
• Uses nanocavity light trapping for single‑molecule sensitivity
• Mobile app enables point‑of‑care diagnostics from a drop of blood
• Achieves >99% accuracy across multiple disease biomarkers
• Aims to accelerate personalized medicine and drug development

Pulse Analysis

Rapid molecular diagnostics have long been hampered by the time‑intensive nature of polymerase chain reaction (PCR), which requires multiple amplification cycles before results are available. The NTU biochip sidesteps this bottleneck by coupling nanophotonic cavities with AI‑driven image analysis, delivering clinically relevant data in a fraction of the time. This shift not only shortens patient wait times but also reduces laboratory overhead, positioning the technology as a disruptive alternative for hospitals and testing labs seeking efficiency without sacrificing sensitivity.

At the heart of the platform is a nanocavity structure that traps light, amplifying fluorescent signals emitted when target microRNAs bind to probes. This design enables detection of single‑molecule events, a feat previously unattainable in routine diagnostics. Complementing the hardware, a deep‑learning model automatically classifies and quantifies signals across thousands of cavities, achieving accuracy rates exceeding 99% and eliminating manual counting errors. The system’s ability to simultaneously assess multiple microRNAs from a minimal blood sample expands its utility across cardiovascular, cancer, neurodegenerative, and metabolic disease panels.

Beyond the laboratory, the integration of a colour camera and a mobile‑phone application transforms the biochip into a portable point‑of‑care tool. Clinicians can obtain near‑instant results in remote or resource‑limited settings, facilitating early disease detection and real‑time treatment monitoring. For pharmaceutical companies, the high‑throughput capability accelerates biomarker validation and therapeutic screening. As NTU seeks industry partnerships to scale production, the biochip could become a cornerstone of personalized medicine, delivering rapid, accurate insights that inform both patient care and drug development strategies.